Fisetin-loaded nanostructured lipid carriers
Fisetin-loaded nanostructured lipid carriers has been studied in 1 paper since 2023: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 31, 2023: “Fisetin-Loaded Nanostructured Lipid Carriers: Formulation and Evaluations against Advanced and Metastatic Melanoma”.
1 paper studies it4 findingsUpdated
See all 1 papers on fisetin-loaded nanostructured lipid carriers
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Anusandhan National Research Foundation and 1 more
- Animals1
What did studies of fisetin-loaded nanostructured lipid carriers find?
4Studies of fisetin-loaded nanostructured lipid carriers measured 4 outcomes, among them NFE2L2, BAX and melanoma-associated metastasis.
NFE2L2
upin cells1
1 study
NFE2L2
upin cells1
Fisetin-loaded nanostructured lipid carriers increase NFE2L2 in cells (NQO1 expression also increased).
“Reverse transcriptase polymerase chain reaction (RT-PCR) and Western blot results show enhanced expression of Nrf2/NQO1 genes”
CellsNQO1 expression also increasednanostructured lipid carriers (Fis-NLCs)
Molecular pharmaceutics
BAX
upin cells1
1 study
BAX
upin cells1
Fisetin-loaded nanostructured lipid carriers increase BAX in cells (compared with pure fisetin; p53 also increased) (~2-fold higher than pure Fis).
“The protein levels of BAX and p53 were ∼2-fold higher compared with that of pure Fis.”
Cellscompared with pure fisetin; p53 also increasednanostructured lipid carriers (Fis-NLCs)
Molecular pharmaceutics
Melanoma-associated metastasis
downin animals1
1 study
Melanoma-associated metastasis
downin animals1
Fisetin-loaded nanostructured lipid carriers decrease melanoma-associated metastasis (compared with pure fisetin) (5.9-fold (lungs) and 10.7-fold (liver) higher inhibition).
“In-vivo studies demonstrated 5.9- and 10.7-fold higher inhibition in melanoma-associated metastasis in the lungs and liver, respectively.”
Animalscompared with pure fisetinnanostructured lipid carriers (Fis-NLCs)lung and liver
Molecular pharmaceutics
IC50 in melanoma cells
downin cells1
1 study
IC50 in melanoma cells
downin cells1
Fisetin-loaded nanostructured lipid carriers decrease IC50 in melanoma cells in cells (compared with pure fisetin) (at least ~3.2 times lower than Fis).
“Fis-NLCs depicted at least ∼3.2 times lower IC50 value and ∼1.8 times higher drug uptake at 48 h in A-375 and B16F10 cells compared to that of Fis.”
Cellscompared with pure fisetinnanostructured lipid carriers (Fis-NLCs)48 h
Molecular pharmaceutics